This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.
In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.
In your application messsage, please share your background and what you can contribute to the group.
Company Overview and News
AUDUBON, Pa., July 16, 2018 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal solutions company, will announce its financial results for the second quarter ended June 30, 2018 after the market close on Wednesday, August 1, 2018. A copy of the release will be available on the Globus Medical website at www.globusmedical.com/investors.
AUDUBON, Pa., July 11, 2018 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal solutions company, will showcase its advanced technologies at the Scoliosis Research Society’s (SRS) 25th Annual International Meeting on Advanced Spine Techniques (IMAST) being held July 11-14, 2018, in Los Angeles, California. The company will also highlight its robotics platform technology through an industry workshop at IMAST, ExcelsiusGPS® First Clinical Experiences, featuring its revolutionary robotic guidance and navigation system on July 13 from 12:00-1:00 pm led by Dr.
AUDUBON, Pa., July 03, 2018 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal solutions company, announced today the expansion of its orthopedic trauma product portfolio with two new product offerings, the ANTHEM® Ankle Fracture System and the ANTHEM® Proximal Humerus Fracture System, marking the Trauma division’s fourth and fifth comprehensive product launches over the last 10 months.
ATHTF GMED ANTM ANTX
Investors interested in stocks from the Medical - Instruments sector have probably already heard of Integer (ITGR - Free Report) and Globus Medical (GMED - Free Report) . But which of these two stocks presents investors with the better value opportunity right now? Let's take a closer look.
Are you ready? Artificial intelligence (AI) isn’t just for tech companies. Biotech stocks are also capitalizing on AI’s potential to deliver revolutionary drugs and speed up drug discovery. A recently released report by Accenture reveals that AI in healthcare could become a $6.6 billion industry by 2021. This is up from just $600 million in 2014.
IBM JNJ GOOGL GMED TRXC GOOG MDT
AUDUBON, Pa., June 13, 2018 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal solutions company, today announced the launch of the CREO® Fenestrated Screw System used in the treatment of patients with advanced stage tumors of the thoracolumbar spine. CREO® fenestrated screws, when augmented with the company’s FORTRESS™ radiopaque bone cement, are designed to restore the structural integrity of the spine at vertebral levels affected by metastatic bone disease.
Cantor Fitzgerald is starting coverage on biotech companies in the spinal segment, a market that the investment house thinks has a $9-billion global market opportunity. Already, patients need medical devices for knees and hips, but the spine could be an even bigger orthopedic market.
OFIX KTWO SPNE GMED
But its new spinal robotic navigation platform, the ExcelsiusGPS, seems to be off to a flying start and could drive sales from multiple angles.
WFC WFCNP WFC.WS WFC.PRL GMED WFC.PRJ WFC.PRT WFC.PRR WFC.PRQ WFC.PRP WFC.PRO WFC.PRN WFC.PRY WFC.PRX WFC.PRW MZOR WFC.PRV
AUDUBON, Pa., May 21, 2018 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal solutions company, today announced the appointment of Daniel Gregoris to Vice President of Sales for the company’s emerging Orthopedic Trauma division. Gregoris will be responsible for leading the growth and expansion of Globus Medical’s direct Trauma sales force and the development and execution of all domestic sales strategies within the Trauma business unit.
AUDUBON, Pa., May 10, 2018 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal solutions company, announced today it is sponsoring the Society of Lateral Access Surgery’s (SOLAS®) newly developed Partnership Program as that organization’s first corporate Alliance Partner. SOLAS® is a non-profit organization that strives to shape the future of lateral access spine surgery through collaboration among members, exchange of ideas, and the promotion of new techniques that benefit patients, physicians and hospitals.
Document Table of Contents UNITED STATES
38m - Asif
History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...
2h - Asif
Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...
22h - Asif
General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...
Silicon Investor Message Boards
This table lists all message boards related to GMED / Globus Medical, Inc. on message board site Silicon Investor.
|GMED - GenoMed Inc.||SCRM: ScreamingMedia.com|
as of ET